aβ42, human

β-Amyloid (1-42), human, Ala(13C3,15N) TFA is a β-Amyloid (1-42), human marked with 13C and 15N. This unprocessed HFIP peptide comprises 42 amino acids and is a brain-permeable amyloid fragment, useful for researching Alzheimer's and Down syndrome. In monomer form, β-Amyloid (1-42), human provides antioxidant and neuroprotective effects. Upon HFIP monomerization and DMSO solvent preparation, it forms soluble oligomers (AβOs) at 4°C, which exhibit synaptotoxicity and neurotoxicity, while at 37°C it forms insoluble fibrils with lower neurotoxicity, involved in oxidative damage. Aβ42 oligomers interact with neuronal surface receptors such as PrPc, mGluR5, and NMDA receptor, activating signaling pathways that induce oxidative stress, calcium imbalance, synaptotoxicity, leading to neuronal dysfunction and death.

Human beta-amyloid protein 42 (1-7) is a bioactive chemical.

GIP (3-42), human acetate is an antagonist of a glucose-dependent insulinotropic polypeptide (GIP) receptor and regulates insulin secretion and GIP metabolism in vivo.

β-Amyloid (42-1), human TFA is an inactive form of the amyloid β peptide (1-42) composed of 42 amino acids, which plays a key role in the pathogenesis of Alzheimer's disease and is commonly used to establish Alzheimer's disease animal models.

[Tyr0] Gastric Inhibitory Peptide (23-42), human, is a glucose-dependent insulinotropic polypeptide (GIP) that modestly inhibits gastric acid secretion while enhancing insulin secretion, making it relevant for research on diabetes and obesity [1] [2].

Biotin-β-Amyloid (1-42), human TFA, also known as Biotin-Amyloid β-Peptide (1-42) (human) TFA, is a biotin-labeled 42-amino acid peptide implicated in the pathogenesis of Alzheimer's disease.

Gastric inhibitory peptide 1 (GIP-1) (3-42), a fragment of the incretin hormone GIP and antagonist to the GIP receptor, is generated through the action of serum dipeptidyl peptidase 4 (DDP-4). When administered at 25 nmol/kg to an ob/ob mouse diabetes model, GIP-1 (3-42) elevates plasma glucose levels and lowers plasma insulin levels, demonstrating its effect on reducing insulin secretion from BRIN-BD11 pancreatic cells at a concentration of 100 nM.

β-Amyloid (42-1), human is the inactive form of amyloid β peptide (1-42), consisting of 42 amino acids. It plays a key role in the pathogenesis of Alzheimer's disease and is commonly used to induce Alzheimer's disease models.

Amyloid β Peptide (42-1)(human) acetate is the inactive form of Amyloid β Peptide (1-42). Amyloid β Peptide (42-1)(human) acetate is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease.

UL75 (14-42), a polypeptide, is a sequence from Human herpesvirus 5.

5-FAM-β-Amyloid (1-42), human (5-FAM-Amyloid β-peptide (1-42) (human) TFA) is a β-Amyloid (1-42), human variant labeled with 5-FAM.

γ-Secretase modulator 4 is a potent γ-secretase modulator that reduces Aβ42 levels with IC50s of 0.017 μM in mice and 0.014 μM in humans.

1. Licochalcone B (LCB) inhibits the proliferation of human malignant bladder cancer cell lines (T24 and EJ) in vitro and antitumor activity in vivo in MB49 (murine bladder cancer cell line) tumor model. 2. LCB and Licochalcone D(LCD) significantly reduce

MEDI-1814 is a fully human IgG1 antibody targeting the C-terminus of Aβ42. It binds to and eliminates circulating Aβ peptides, thereby preventing their aggregation into toxic oligomers. MEDI-1814 is applicable in Alzheimer's disease research. For an isotype control, refer to HumanIgG1kappa, Isotype Control.